Skip to main content

Table 4 Glucose metabolism parameters in women with prior menstrual disorders and controls before and after HRT

From: Effects of hormone replacement therapy on glucose and lipid metabolism in peri- and postmenopausal women with a history of menstrual disorders

Variable

Perimenopausal

Postmenopausal

Normal menstruation

(N = 410)

Menstrual disorders

(N = 46)

P valuea

Normal menstruation

(N = 120)

Menstrual disorders

(N = 19)

P valuea

FPG (mmol/L)

 Before HRT

5.23 (4.93, 5.53)

5.14 (4.85, 5.49)

0.25

5.33 (5.00, 5.63)

5.50 (4.84, 5.97)

0.40

 After HRT

5.13 (4.87, 5.41)

5.02 (4.81, 5.58)

0.49

5.12 (4.93, 5.41)

5.18 (4.85, 5.32)

0.75

P valueb

0.000

0.64

 

0.000

0.002

 

 Δ FPG† (mmol/L)

−0.10(− 0.42, 0.18)

0.01(− 0.37,0.19)

0.36

− 0.17(− 0.44, 0.07)

−0.37(− 0.67, 0.06)

0.11

FIN (mU/L)

 Before HRT

5.60 (4.30, 7.34)

5.82 (4.73,7.63)

0.26

5.83 (4.10, 8.16)

6.25 (3.40, 7.73)

0.93

 After HRT

5.03 (3.79, 6.37)

5.10 (4.08, 7.03)

0.36

4.75 (3.50, 6.20)

4.50 (3.10, 6.10)

0.97

P valueb

0.000

0.006

 

0.000

0.12

 

 Δ FIN† (mU/L)

−0.70(−2.34, 0.60)

−0.60(−1.91, 0.00)

0.86

−1.07(−2.51, 0.36)

− 0.20(−3.10, 1.10)

0.80

HOMA-IR

 Before HRT

1.29 (0.98, 1.74)

1.37 (1.05,1.83)

0.38

1.37 (0.96, 1.96)

1.62 (0.84, 1.88)

0.81

 After HRT

1.15 (0.85, 1.51)

1.20 (0.88, 1.61)

0.43

1.05 (0.76, 1.47)

1.06 (0.70, 1.47)

1.00

P valueb

0.000

0.008

 

0.000

0.05

 

 Δ HOMA-IR†

−0.17(−0.59, 0.13)

−0.18(− 0.49, 0.09)

0.89

− 0.28(− 0.67, 0.03)

−0.19(− 0.92, 0.15)

0.88

  1. Data are expressed as medians (25th percentile, 75th percentiles). P < 0.05 was considered significant. †Value of the difference between the baseline and follow-up serum glucose metabolism parameters (FPG, FIN, and HOMA-IR). aP values are for between-group differences by Mann-Whitney U test or independent samples t-test. bP values are for within-group differences by Wilcoxon signed-rank test or paired-samples t test
  2. Others: FIN fasting insulin, FPG fasting plasma glucose, HOMA-IR homeostasis model assessment of insulin resistance, HRT hormone replacement therapy